Clinical Trials Logo

Clinical Trial Summary

Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients receiving chemotherapy for leukemia, or submitted to stem cell transplantation. Patients with a history of invasive fungal infection (IFI) are at high risk of developing relapse and fatal complications.

Prompt intensive antifungal therapy, have improved responses and survival, allowing an increase of antifungal treatments, including secondary antifungal prophylaxis.

Few studies have addressed the role of previous IFI in the feasibility of stem cell transplant, or the secondary prophylaxis with antifungal drugs in preventing recurrence of infection after transplantation. However, given the lack of prospective studies, the role of secondary antifungal prophylaxis remains unclear.

Itraconazole is a wide-spectrum triazole antifungal agent active against Candida albicans, non-albicans, Aspergillus spp., Blastomyces dermatitidis, Blastomyces coccidioides, Cryptococcus neoformans, Sporothrix schenkii, Paracoccidioides brasiliensis, Histoplasma spp. and various kinds of yeast fungi and mycetes.

The role of itraconazole IFI prophylaxis treatment has been proved by many interventional studies. In this prospective, multicentric study of secondary prophylaxis, itraconazole will be given at standard dose to patients undergoing allogeneic stem cell transplantation or chemotherapy with prior invasive fungal infection, to assess the efficacy and safety of itraconazole secondary prophylaxis.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01198236
Study type Interventional
Source Zhejiang University
Contact
Status Completed
Phase Phase 4
Start date July 2008
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT01888458 - Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD) Phase 2
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Completed NCT03066011 - Registry of Patients Treated With Systemic Mold-Active Triazoles
Completed NCT04004078 - An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
Completed NCT01576653 - Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL N/A
Enrolling by invitation NCT02510053 - Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit N/A
Recruiting NCT06137690 - Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
Completed NCT01783379 - Pharmacokinetics of Micafungin in Patients Intensive Care Unit
Completed NCT01533558 - Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Recruiting NCT03149562 - Association of Plasma Transfusions and Invasive Fungal Infection
Recruiting NCT04665037 - Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) Phase 2
Withdrawn NCT01185405 - Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients N/A
Terminated NCT01148160 - Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy N/A
Completed NCT00893555 - Pharmacologic Optimization of Voriconazole Phase 3
Unknown status NCT00460330 - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT N/A
Completed NCT02823132 - Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia N/A